论文部分内容阅读
1 资料和方法 1.1 病例选择 62例患者在临床诊断基础上检测抗-HCV和HCV-RNA均呈双阳性。病程不足半年为急性(23例),半年以上为慢性(39例),男37例,女25例,年龄最小14岁、最大71岁。 1.2 治疗方案 治疗组:依A、B两种方案。病人根据经济能力任选一种。采用美国先灵葆雅药厂生产的基因工程干扰素α-2b(干扰
1 Materials and Methods 1.1 Case Selection 62 patients on the basis of clinical diagnosis of anti-HCV and HCV-RNA showed double positive. Less than half a year course of acute (23 cases), more than six months for the chronic (39 cases), 37 males and 25 females, the youngest 14 years old, maximum 71 years old. 1.2 treatment group treatment group: according to A, B two programs. Patients according to the economic ability of an optional. The use of the United States Scheringutzer pharmaceutical production of genetically engineered interferon α-2b (interference